Clinical ResearchPreventive CardiologyOn-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy: JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Key Words
Abbreviations and Acronyms
Cited by (0)
The JUPITER trial was financially supported by AstraZeneca, who collected the trial data and monitored the study sites but had no role in the conduct of the analyses, in drafting this report, or in the decision to submit these analyses for publication. Dr. Mora received research grant support from the National Heart, Lung, and Blood Institute (K08 HL094375), AstraZeneca, and Merck & Co.; served as a consultant for Pfizer and Quest Diagnostics; and received nonpromotional speaker honorarium from Abbott. Dr. Glynn received grant support from AstraZeneca, Novartis, and Bristol-Myers Squibb; and has a consulting agreement with Merck. Dr. Boekholdt has served as a consultant to Pfizer. Dr. Nordestgaard has served as a consultant for AstraZeneca, Abbott, Merck & Co., and Pfizer. Dr. Kastelein is a recipient of the Lifetime Achievement Award (2010T082) of the Dutch Heart Foundation; and is a consultant for and has received research grants from AstraZeneca. Dr. Ridker received research support from AstraZeneca, Novartis, Roche, and Sanofi-Aventis, and nonfinancial research support from Amgen. Dr. Ridker is coinventor on patents held by Brigham and Women's Hospital related to the use of inflammatory biomarkers in cardiovascular disease that have been licensed to Siemens and AstraZeneca; has served as a research consultant to Schering-Plough, Sanofi/Aventis, Isis, Siemens, Abbott, Merck, and Vascular Biogenics; and has received research grants from AstraZeneca.